India-based Morepen Laboratories, a global leader in Active Pharmaceutical Ingredient (API) manufacturing, has received ...
Patent cliffs will be one of the originator's biggest pain points in the next 3-5 years. Between the originator and bios...
By 2030, pharmaceutical companies are expected to lose over $236 billion in revenue due to the impending ‘patent c...
Japan-headquartered pharmaceutical firm Eisai has entered into an exclusive license agreement with a subsidiary of SciCl...
Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufactur...
Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, ...
Industries with international operations face increasing vulnerability to supply chain disruptions. This risk is particu...
Apexelsin, a generic drug from China been approved by the European Commission. Apexelsin is a generic dru...
The China Association for Science and Technology (CAS) Consortium of Life Sciences Societies is proud to announce the ...
The third edition of the "Asia Pacific Forum on Precision Cancer Treatment" concluded today with a dynamic exchange of i...
How did the company perform during FY 2022-23? The company is currently in a recovery phase following the impact ...
The Medicines Patent Pool (MPP), a United Nations-backed public health organisation, has signed sublicence agreemen...
Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Indian pharmaceutical company Dr. Reddy’s Laboratories, ...
Indian pharmaceutical company Venus Remedies has received marketing authorisation for its generic cancer drugs from Uzbe...
Trans-Atlantic private equity healthcare specialist ArchiMed has invested in Bielefeld, Germany-based PlasmidFactory. Fo...
Pharmaceutical companies need to ensure they have a competitive edge in the market while adapting to evolving industry b...
The Medicines Patent Pool (MPP) has signed agreements with 35 companies to manufacture the generic version of Pfizer's o...
Eisai Co. has announced that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inh...
